-
1 Comment
Memphasys Limited is currently in a long term downtrend where the price is trading 26.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has increased by 3.7% to $-719K since the same quarter in the previous year.
Finally, its free cash flow grew by 124.3% to $363K since the same quarter in the previous year.
Based on the above factors, Memphasys Limited gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Exchange | AU |
| CurrencyCode | AUD |
| ISIN | AU000000MEM5 |
| Industry | Medical Devices |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Market Cap | 16M |
| Beta | 0.26 |
| Dividend Yield | None |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MEM.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
